The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.
In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health […]
Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
Taken from the Annals of Internal Medicine, these clinical guidelines describe best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with these four infections: acute bronchitis with chronic obstructive pulmonary disease (COPD) exacerbation, community-acquired pneumonia (CAP), urinary tract infections (UTIs), and cellulitis.
In this MedPage Today interview with Jason Karlawish, MD, co-director of the Penn Memory Center at the University of Pennsylvania in Philadelphia and author of the new book, The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, the biomarker “revolution” is […]
The numbers are staggering: fifty million people worldwide live with dementia, with the number expected to reach 152 million in 2050. Despite these seemingly overwhelming totals, the neurocognitive health of you and your patients is highly dependent on multiple factors. Here are five of them, all supported by evidence-based studies.
US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does […]
The IRS was kind enough to move the traditional tax deadline from April 15 to Monday, May 17, granting a bit of a reprieve for getting your financial affairs in order. Many physicians choose to handle their taxes themselves despite a good CPA paying for him/herself in the deductions and tax-savings strategies that they find […]
The numbers are staggering when it comes to heart disease, and it’s still the No. 1 killer in the US, according to the CDC. With 30.3 million American adults—12.1% of the adult population—diagnosed with heart disease, it’s certainly a struggle to keep it at bay, but there are preventive measures you can take. Here are […]
From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ)carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.